RSPI Stock Overview
Engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
RespireRx Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0018 |
| 52 Week High | US$0.0069 |
| 52 Week Low | US$0.0002 |
| Beta | 0.73 |
| 1 Month Change | 157.14% |
| 3 Month Change | 200.00% |
| 1 Year Change | 24.14% |
| 3 Year Change | -88.71% |
| 5 Year Change | -99.81% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RSPI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -25.0% | 0.2% | 0.2% |
| 1Y | 24.1% | 1.3% | 22.0% |
Return vs Industry: RSPI exceeded the US Pharmaceuticals industry which returned 1.3% over the past year.
Return vs Market: RSPI exceeded the US Market which returned 22% over the past year.
Price Volatility
| RSPI volatility | |
|---|---|
| RSPI Average Weekly Movement | 141.1% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RSPI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RSPI's weekly volatility (141%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Arnold Lippa | www.respirerx.com |
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company’s lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea.
RespireRx Pharmaceuticals Inc. Fundamentals Summary
| RSPI fundamental statistics | |
|---|---|
| Market cap | US$949.46k |
| Earnings (TTM) | -US$2.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs RSPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSPI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.17m |
| Earnings | -US$2.17m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0023 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -22.6% |
How did RSPI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 23:16 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RespireRx Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| J. McCarthy | NOBLE Capital Markets, Inc. |